Publications by authors named "Prince Asumadu Adu"
Background: We evaluated the association of hepatitis B virus (HBV) treatment with all-cause, and liver-related mortality among individuals with HBV and cirrhosis in British Columbia (BC), Canada.
Methods: This analysis included people diagnosed with HBV and had cirrhosis in the BC Hepatitis Testers Cohort, including data on all individuals diagnosed with HBV from 1990 to 2015 in BC and integrated with healthcare administrative data. We followed people with cirrhosis from the first cirrhosis diagnosis date until death or December 31, 2020.
Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, Canada.
Lancet Reg Health Am
January 2024
Background: HCV infection is associated with mortality due to extrahepatic manifestations (EHM). Sustained virologic response (SVR) following direct-acting antiviral (DAA) therapy has been linked to decreased all-cause and liver-related mortality. However, evidence regarding the impact of DAA on EHM-related deaths is lacking.
View Article and Find Full Text PDFBackground: Face mask use has been associated with declines in COVID-19 incidence rates worldwide. A handful of studies have examined the factors associated with face mask use in North America during the COVID-19 pandemic; however, much less is known about the patterns of face mask use and the impact of mask mandates during this time. This information could have important policy implications, now and in the event of future pandemics.
View Article and Find Full Text PDFArticle Synopsis
- Limited data exists on the impact of HBV infection and related conditions on liver-related deaths in Canada, particularly in British Columbia.
- A study using the BC Hepatitis Testers Cohort found that liver-related mortality rates are significantly higher in individuals with HBV compared to those without, especially in cases of HBV mono-infection, HBV with non-alcoholic fatty liver disease (NAFLD), and HBV with hepatitis C virus (HCV) coinfection.
- The findings emphasize the importance of diagnosing and treating both viral and fatty liver diseases to reduce liver-related health issues and deaths.
Article Synopsis
- Chronic infection with hepatitis C virus (HCV) significantly raises the risk of liver cancer and certain extrahepatic cancers, but past studies on extrahepatic malignancies have yielded mixed results due to various limitations.
- Using data from the British Columbia Hepatitis Testers Cohort, the study analyzed cancer incidence among over 56,000 individuals tested for HCV compared to around 1.2 million individuals who tested negative from 1990-2016.
- Results indicated that those with HCV had a substantially higher risk for cancers such as liver, anal, and lung, while also identifying that individuals with HCV were generally younger, had more comorbidities, and were more often socially deprived than those without HCV
Introduction: Increasing evidence indicates that chronic hepatitis C virus (HCV) infection is associated with higher risk of diabetes. Previous studies showed ethnic disparities in the disease burden of diabetes, with increased risk in Asian population. We described the incidence of type 2 diabetes related to HCV infection and assessed the concurrent impact of HCV infection and ethnicity on the risk of diabetes.
View Article and Find Full Text PDFBackground & Aims: HCV infection is associated with several extrahepatic manifestations (EHMs). We evaluated the impact of sustained virological response (SVR) on the risk of 7 EHMs that contribute to the burden of extrahepatic disease: type 2 diabetes mellitus, chronic kidney disease or end-stage renal disease, stroke, ischemic heart disease, major adverse cardiac events, mood and anxiety disorders, and rheumatoid arthritis.
Methods: A longitudinal cohort study was conducted using data from the British Columbia Hepatitis Testers Cohort, which included ~1.